| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Leucine zipper putative tumor suppressor 2 {ECO:0000255|HAMAP-Rule:MF_03026}, hLZTS2, Protein LAPSER1 {ECO:0000255|HAMAP-Rule:MF_03026}, LZTS2 {ECO:0000255|HAMAP-Rule:MF_03026} |
| Entrez GeneID | 84445 |
| WB Predicted band size | 72.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This LZTS2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 572-601 amino acids from the C-terminal region of human LZTS2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LZTS2抗体的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **文献名称**: *LZTS2 suppresses tumor progression via regulating CDK1 phosphorylation in breast cancer*
**作者**: Zhang Y, et al.
**摘要**: 本研究通过Western blot和免疫组化技术，利用LZTS2特异性抗体，发现LZTS2在乳腺癌组织中低表达，且其缺失与CDK1异常激活相关。实验表明，LZTS2过表达可通过抑制CDK1磷酸化延缓肿瘤生长。
---
2. **文献名称**: *LZTS2 antibody-based profiling reveals its role in prostate cancer cell invasion*
**作者**: Smith RJ, et al.
**摘要**: 通过LZTS2单克隆抗体进行组织芯片分析，发现LZTS2在前列腺癌转移灶中显著下调。体外实验证实，LZTS2敲低促进癌细胞侵袭，其机制可能与调控上皮-间质转化(EMT)信号通路有关。
---
3. **文献名称**: *Development and validation of a novel anti-LZTS2 monoclonal antibody for functional studies*
**作者**: Tanaka K, et al.
**摘要**: 文章报道了一种高特异性兔源LZTS2单克隆抗体的开发，并通过ELISA、免疫荧光和流式细胞术验证其效价。该抗体成功应用于检测LZTS2与β-catenin的相互作用，提示其在Wnt信号通路中的潜在功能。
---
4. **文献名称**: *LZTS2 modulates DNA damage response through ATM/ATR signaling in glioblastoma*
**作者**: Chen L, et al.
**摘要**: 利用LZTS2抗体进行免疫共沉淀实验，发现LZTS2与ATM激酶存在物理结合。研究表明，LZTS2缺失导致DNA损伤修复能力下降，提示其在胶质母细胞瘤治疗耐药性中的作用。
---
**注意**：以上文献为模拟生成，实际研究中请通过PubMed、Google Scholar等平台检索真实文献(关键词：LZTS2 antibody, leucine zipper tumor suppressor 2. cancer)。
The LZTS2 (Leucine Zipper Tumor Suppressor 2) antibody targets a protein encoded by the LZTS2 gene, also known as LAPSER1 or PROCAM1. This gene belongs to the LZTS family, characterized by leucine zipper motifs that mediate protein-protein interactions. LZTS2 is implicated in tumor suppression, with studies linking its expression loss to cancer progression. Located on chromosome 10q23-q24. a region frequently altered in malignancies, LZTS2 is epigenetically silenced in various cancers, including prostate, breast, and gliomas, often through promoter hypermethylation.
Functionally, LZTS2 regulates cell cycle progression, genomic stability, and cytoskeletal organization. It interacts with key proteins like β-catenin and Aurora A kinase, modulating Wnt signaling and mitotic spindle formation. Reduced LZTS2 expression correlates with poor prognosis, enhanced metastasis, and chemoresistance, suggesting its role in epithelial-mesenchymal transition (EMT) and cancer cell invasiveness.
LZTS2 antibodies are primarily used in research to detect protein expression via immunohistochemistry (IHC), western blotting, or immunofluorescence (IF). These tools help elucidate LZTS2's molecular mechanisms and its potential as a diagnostic or prognostic biomarker. However, antibody specificity and validation remain critical due to homology within the LZTS family. Ongoing studies aim to clarify its therapeutic relevance in targeting cancer pathways.
×
